Older people have vaccines available to prevent severe influenza and COVID-19, but there’s been nothing to protect against the third respiratory virus that contributed to this season’s wretched “triple-demic.”
Until now.
Two major pharmaceutical companies published clinical trial results this week that pave the way for an RSV (respiratory syncytial virus) vaccine to be available for adults by the time next cold and flu season rolls around.
“RSV continues to be the last of the major winter respiratory viruses for which we don’t have a vaccine, but as these two articles in the New England Journal of Medicine indicate, we’re getting close,” said Dr. William Schaffner. He is medical director of the National Foundation for Infectious Diseases, in Bethesda, Md.
